AB Science
AB Science
Explore linked clinical trials.5 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Clinical Impact Through AI-assisted MS Care - A Retrospective Multi-center Observational Study. | CNS demyelinating autoimmune disease, Disease Attributes, Disease Progression, Pathologic Processes, Pathological Conditions, Signs and Symptoms, acute transverse myelitis, autoimmune disease, autoimmune disorder of the nervous system, cranial nerve neuropathy, demyelinating disease, eye disorder, immune system disorder, multiple sclerosis, myelin oligodendrocyte glycoprotein antibody-associated disease, nervous system disorder, neuromyelitis optica, optic nerve disorder, optic neuritis | Recruiting | Not stated | 2025-12-12 | NCT06280755 | |
| Efficacy and Safety of Masitinib in Combination With SoC Versus Placebo in the Treatment of ALS Patients | Nutritional and Metabolic Diseases, TDP-43 proteinopathy, amyotrophic lateral sclerosis, central nervous system disorder, metabolic disease, motor neuron disorder, nervous system disorder, neurodegenerative disease, neuromuscular disease, proteostasis deficiencies, spinal cord disorder | Not yet recruiting | Phase 3 | 2025-10-03 | NCT07174492 | |
| Masitinib in Patients With Mild Alzheimer's Disease | Alzheimer disease, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Not yet recruiting | Phase 3 | 2025-10-03 | NCT05564169 | |
| AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, GATA2 deficiency with susceptibility to MDS/AML, Hemic and Lymphatic Diseases, Myelodysplastic Syndrome Acute Myeloid Leukemia, Neoplasms by Histologic Type, acute myeloid leukemia, bone marrow disorder, hematologic disorder, hereditary disease, leukemia, myelodysplastic syndrome, myeloid leukemia, neoplasm | Recruiting | Phase 1 / Phase 2 | 2025-10-02 | NCT05211570 | |
| Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients | Nutritional and Metabolic Diseases, TDP-43 proteinopathy, amyotrophic lateral sclerosis, central nervous system disorder, metabolic disease, motor neuron disorder, nervous system disorder, neurodegenerative disease, neuromuscular disease, proteostasis deficiencies, spinal cord disorder | Recruiting | Phase 3 | 2025-09-12 | NCT03127267 |